Myelodysplastic Syndromes
📧 Sign up to get email alerts when something new happens for Myelodysplastic Syndromes.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-09-22Clinical Trial Update: Azacytidine Prior to in Vivo T-cell Depleted Allo Stem Cell Transplant for Patients With Myeloid Malignancies in CR [Phase 2]
A Phase 2 clinical trial evaluated azacytidine prior to in vivo T-cell depleted allogeneic stem cell transplant in patients with myeloid mal…
-
FDA approval · 2021-09-20FDA Approved: DECITABINE — Original Application (Eugia US LLC)
FDA approved Eugia US LLC's original application for a generic decitabine product indicated for myelodysplastic syndromes.
-
CLINICAL_TRIALS trial_result · 2021-08-13Clinical Trial Update: Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer [Phase 2, Phase 3]
Phase 2/Phase 3 trial evaluating combination chemotherapy with donor stem cell transplant for aplastic anemia and hematologic cancers; compl…
-
CLINICAL_TRIALS trial_result · 2021-08-11Clinical Trial Update: TET2 Mutations in Myelodysplastic Syndromes and Acute Myeloid Leukemia With Azacitidine + Ascorbic Acid [Phase 2]
Phase 2 trial updating TET2 mutation targeting with azacitidine plus ascorbic acid in myelodysplastic syndromes and acute myeloid leukemia h…
-
FDA approval · 2021-08-05FDA Approved: LENALIDOMIDE — Supplemental Application (Teva Pharmaceuticals, Inc.)
FDA approved a supplemental application for lenalidomide by Teva Pharmaceuticals, approving changes related to the drug's use.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
EMA withdrawal · 2021-08-04EMA Withdrawn: Azacitidine Celgene (azacitidine) — Celgene Europe BV
The EMA has withdrawn the azacitidine product Celgene Europe BV from the market.
-
FDA approval · 2021-06-25FDA Approved: DECITABINE — Supplemental Application (Mylan Institutional LLC)
FDA approved a supplemental application for decitabine (generic) submitted by Mylan Institutional LLC.
-
CLINICAL_TRIALS trial_result · 2021-06-24Clinical Trial Update: Study for the Treatment of Transfusional Iron Overload in Myelodysplastic Patients [Phase 4]
Phase 4 clinical trial update for treating transfusional iron overload in patients with myelodysplastic syndromes; study completed with resu…
-
CLINICAL_TRIALS trial_result · 2021-06-16Clinical Trial Update: Oral Rigosertib in Low Risk MDS Patients Refractory to ESAs [Phase 2]
Phase 2 trial update for oral rigosertib in low-risk myelodysplastic syndromes patients refractory to ESAs.
-
CLINICAL_TRIALS trial_result · 2021-06-11Clinical Trial Update: Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation [Phase 2]
Phase 2 trial update on Total Body Irradiation with or without Total Lymphoid Irradiation and Anti-Thymocyte Globulin in non-myeloablative h…
-
CLINICAL_TRIALS trial_result · 2021-06-09Clinical Trial Update: Sodium Stibogluconate in the MDS/AML With One of the 65 Defined p53 Mutations [Phase 2]
Phase 2 clinical trial investigating sodium stibogluconate in myelodysplastic syndromes and acute myeloid leukemia with specific p53 mutatio…
-
FDA approval · 2021-04-12FDA Approved: DECITABINE — Original Application (Qilu Pharmaceutical Co., Ltd.)
The FDA approved an original ANDA for decitabine from Qilu Pharmaceutical Co., Ltd.
-
FDA approval · 2021-03-17FDA Approved: DECITABINE — Supplemental Application (BluePoint Laboratories)
The FDA approved a supplemental application for decitabine by BluePoint Laboratories, authorizing a generic version of the drug.
-
CLINICAL_TRIALS trial_result · 2021-03-16Clinical Trial Update: Safety and Activity of Digoxin With Decitabine in Adult AML and MDS [Phase 1, Phase 2]
Phase 1/2 trial evaluating safety and activity of digoxin in combination with decitabine for adults with acute myeloid leukemia and myelodys…
-
CLINICAL_TRIALS trial_result · 2021-03-05Clinical Trial Update: Outpatient Induction Chemotherapy in Treating Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome [NA]
Clinical trial update for outpatient induction chemotherapy in adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome; trial complet…
-
CLINICAL_TRIALS trial_result · 2021-02-08Clinical Trial Update: A Study of ARRY-520 in Patients With Advanced Myeloid Leukemia [Phase 1, Phase 2]
Phase 1/2 study of ARRY-520 in advanced myeloid leukemia and myelodysplastic syndromes has completed.
-
CLINICAL_TRIALS trial_result · 2021-01-27Clinical Trial Update: Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome [Phase 2]
Phase 2 trial comparing antithymocyte globulin to supportive care in myelodysplastic syndromes has completed.
-
CLINICAL_TRIALS trial_result · 2020-12-21Clinical Trial Update: Phase I/II Trial to Investigate BI 836858 in Myelodysplastic Syndromes [Phase 2]
Phase II trial update for BI 836858 in myelodysplastic syndromes; study terminated with results posted.
-
CLINICAL_TRIALS trial_result · 2020-12-10Clinical Trial Update: Bone Marrow Transplant in Treating Patients With Hematologic Cancers [Phase 2]
Phase 2 clinical trial update on bone marrow transplant for hematologic cancers (completed).
-
FDA approval · 2020-11-23FDA Approved: DECITABINE — Original Application (Gland Pharma Limited)
FDA approves a new original generic application for decitabine (Gland Pharma Limited).
-
CLINICAL_TRIALS trial_result · 2020-11-23Clinical Trial Update: Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study [Phase 2]
Phase 2 trial update on iron chelation therapy for myelodysplastic syndromes with event-free survival data.
-
FDA approval · 2020-11-10FDA Approved: DECITABINE — Supplemental Application (Mylan Institutional LLC)
The FDA approved a supplemental application for Decitabine submitted by Mylan Institutional LLC under the ANDA process.
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: Non-Myeloablative Conditioning for Unrelated Donor Umbilical Cord Blood Transplant [Phase 2]
Phase 2 trial update on non-myeloablative conditioning for unrelated donor umbilical cord blood transplant completed with posted results.
-
CLINICAL_TRIALS trial_result · 2020-11-02Clinical Trial Update: A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes [Phase 2]
Phase 2 trial of lenalidomide plus azacitidine in low-risk myelodysplastic syndromes (MDS) was terminated.
-
CLINICAL_TRIALS trial_result · 2020-10-12Clinical Trial Update: Cellular Immunotherapy for Patients With High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia [Phase 1, Phase 2]
A clinical trial evaluating cellular immunotherapy for high-risk myelodysplastic syndromes and acute myeloid leukemia in Phase 1/Phase 2.